Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Pecorelli

Showing results (141-150 of 160) with videos related to

Pageof 16
Sort By:
Lancet (London, England)|November 30, 1996
In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI)G S Wengler, A Lanfranchi, T Frusca, et al.
British Journal of Cancer|April 26, 2012
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapyS Bellone, D Roque, E Cocco, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2001
Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group studyH C Wagenaar, S Pecorelli, C Mangioni, et al.
European Journal of Gynaecological Oncology|September 23, 2015
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneumJ Prat, H Belhadj, J Berek, et al.
British Journal of Cancer|September 15, 2011
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumabP Todeschini, E Cocco, S Bellone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology GroupM J Piccart, J A Green, A J Lacave, et al.
British Journal of Cancer|June 19, 2009
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancerE Cocco, S Bellone, K El-Sahwi, et al.
British Journal of Cancer|August 12, 2010
hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinomaE Cocco, Z Hu, C E Richter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 13, 2009
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanesS Pecorelli, I Ray-Coquard, O Tredan, et al.
British Journal of Cancer|November 19, 2009
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinomaK El-Sahwi, S Bellone, E Cocco, et al.
Pageof 16

Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
Lancet (London, England)|November 30, 1996
In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI)G S Wengler, A Lanfranchi, T Frusca, et al.
British Journal of Cancer|April 26, 2012
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapyS Bellone, D Roque, E Cocco, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2001
Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group studyH C Wagenaar, S Pecorelli, C Mangioni, et al.
European Journal of Gynaecological Oncology|September 23, 2015
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneumJ Prat, H Belhadj, J Berek, et al.
British Journal of Cancer|September 15, 2011
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumabP Todeschini, E Cocco, S Bellone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology GroupM J Piccart, J A Green, A J Lacave, et al.
British Journal of Cancer|June 19, 2009
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancerE Cocco, S Bellone, K El-Sahwi, et al.
British Journal of Cancer|August 12, 2010
hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinomaE Cocco, Z Hu, C E Richter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 13, 2009
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanesS Pecorelli, I Ray-Coquard, O Tredan, et al.
British Journal of Cancer|November 19, 2009
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinomaK El-Sahwi, S Bellone, E Cocco, et al.
Pageof 16